Spectrum of practice in the routine management of cervical dystonia with abobotulinumtoxinA: findings from three prospective open-label observational studies

Journal of Clinical Movement Disorders
Vijay P MisraSavary Om

Abstract

Cervical dystonia is a heterogeneous disorder with several possible presentations, for which first-line therapy is often botulinum toxin (BoNT). In routine clinical practice the success of each BoNT injection is dependent on several variables, including individual presentation and injection technique. Large multicenter, observational studies provide important information on individualized administration strategies that cannot be otherwise ascertained from controlled clinical trials. In this meta-analysis of patient level data, we aimed to evaluate the clinical characteristics of patients with cervical dystonia undergoing routine treatment with botulinum toxin, specifically abobotulinumtoxinA. We also aimed to characterize current abobotulinumtoxinA injection techniques and parameters and to explore international differences in patient presentation and treatment. This was a meta-analysis of baseline data from three prospective, international, multicenter, observational studies (NCT01314365, NCT00833196 and NCT01753349) of botulinum toxin treatment for the routine management of adult cervical dystonia. Data presented illustrate the significant heterogeneity of CD presentation in routine practice. Most subjects presented with a co...Continue Reading

References

Oct 31, 2000·Muscle & Nerve·J A Van GerpenP G McManis
Mar 1, 2005·Movement Disorders : Official Journal of the Movement Disorder Society·Daniel TruongGeoffrey L Sheean
Apr 20, 2007·Parkinsonism & Related Disorders·J JankovicC Bergeron
Apr 3, 2010·Parkinsonism & Related Disorders·Daniel TruongUNKNOWN Global Dysport Cervical Dystonia Study Group
May 21, 2010·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·A AlbaneseJ Valls-Solé
Jan 20, 2011·The International Journal of Neuroscience·Andy Pickett, Raymond L Rosales
Jul 19, 2011·Journal of the Neurological Sciences·Cynthia L ComellaUNKNOWN U.S. XEOMIN Cervical Dystonia Study Group
May 12, 2012·Parkinsonism & Related Disorders·S W R NijmeijerM A J Tijssen
May 8, 2013·Movement Disorders : Official Journal of the Movement Disorder Society·Alberto AlbaneseJan K Teller
Dec 6, 2014·Movement Disorders : Official Journal of the Movement Disorder Society·Ji Young YunBeom S Jeon
Dec 31, 2014·Journal of Neural Transmission·Axel SchrammWolfgang H Jost
Jan 18, 2015·Journal of the Neurological Sciences·Joseph JankovicMitchell F Brin
Jan 22, 2015·Journal of Neurology·Cynthia Comella, Kailash Bhatia
Apr 17, 2015·Journal of Neurology·Alberto AlbaneseCharalampos Tzoulis
Sep 23, 2016·Movement Disorders : Official Journal of the Movement Disorder Society·Werner PoewePhilippe Picaut
Apr 23, 2017·Journal of the Neurological Sciences·Richard M TroschCynthia L Comella
Dec 23, 2017·Journal of Neurology·Vijay P MisraUNKNOWN INTEREST IN CD2 study group

❮ Previous
Next ❯

Citations

Mar 28, 2019·Reviews in the Neurosciences·Michał MarciniecKonrad Rejdak
Jul 29, 2021·Clinical Parkinsonism & Related Disorders·Richard M TroschSavary Om

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01314365
NCT00833196
NCT01753349

Software Mentioned

CD
ANCHOR

Related Concepts

Related Feeds

Botulism (ASM)

Botulism is a rare but serious paralytic illness caused by a nerve toxin that is produced by the bacterium clostridium botulinum. Discover the latest research on botulism here.

Botulism

Botulism is a rare but serious paralytic illness caused by a nerve toxin that is produced by the bacterium clostridium botulinum. Discover the latest research on botulism here.

Related Papers

Tremor and Other Hyperkinetic Movements
Virgilio Gerald H Evidente, Eric J Pappert
The Medical Letter on Drugs and Therapeutics
© 2022 Meta ULC. All rights reserved